ZD1839治疗43例晚期非小细胞肺癌的临床观察

Clinical Observation of ZD1839 in the Treatment of Advanced Non-small-cell Lung Cancer

目的 :对转移性非小细胞肺癌患者应用ZD1839后的疗效及不良事件进行观察。方法 :选择 4 3例NSCLC病人 ,给予ZD1839治疗 ,90天后对其疗效及不良反应进行观察统计。结果 :4 3例服用ZD1839的病人中 ,90天后CR率 2 3% ,PR率 16 3% ,SD率 32 6 % ,疾病控制率 (CR +PR +SD) 5 1 2 % ;不良事件观察 :皮疹 4 8 8% ,腹泻 2 7 9% ,转氨酶升高11 6 % ,恶心、呕吐 14 0 % ,未观察到间质性肺炎病例。结论 :从疾病控制和毒副反应结果分析 ,ZD1839是一类可以用于临床的抗肿瘤新药 。

Objective:To observe the curative effect and adverse event of non-small cell lung cancer(NSCLC) patients who took ZD1839.Methods:We chose 43 patients who took ZD1839 and invested the curative effect and adverse event after 90 days.Results:In the 43 patients,CR,PR,SD rate were 2.3%,16.3%,32.6% respectively.Disease control rate was 51.2%.Adverse events:rash,diarrhea,step-up of aminotransferase,nausea and vomiting were reported by 48.8%,27.9%,11.6% and 14.0% respectively.No interstitial lung disease was found.Conclusion:We confirm ZD1839 is a new drug which can be adapted to tumor patients according to its disease control rates and adverse events.It shows good prospect to patient which suffer from advanced and metastatic tumor.